TrialPLoS medicine2025

Immunogenicity and safety of DS-5670d, an omicron XBB.1.5-targeting COVID-19 mRNA vaccine: A phase 3, randomized, active-controlled study.

Ami Kawamoto et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.